Semax Research Guide: Structure, Mechanism, Preclinical Findings and Handling

What Semax is

Semax is a short synthetic peptide used in neuroscience-oriented research as a probe of neurotrophic and neuromodulatory signaling. Its sequence, Met-Glu-His-Phe-Pro-Gly-Pro, has seven residues and a theoretical average mass of about 813–814 Da. The first four residues match positions 4–7 of adrenocorticotropic hormone (ACTH); the final three, Pro-Gly-Pro, are an added tail that protects the molecule from enzymatic breakdown. Literature sometimes describes the parent region as ACTH(4-10) and sometimes as ACTH(4-7), which is why exact sequence documentation is more reliable than shorthand names. An introductory summary is available at what is Semax peptide.

The peptide is notable for what it does not share with its parent hormone. Full-length ACTH stimulates the adrenal cortex through the melanocortin 2 receptor, and the regions of the hormone responsible for that steroidogenic activity are absent from this short fragment. Semax can therefore be studied without adrenal stimulation as a confound, and it occupies its own niche among research peptides, separate from the melanocortin-agonist and growth-hormone families.

Semax is frequently studied beside Selank, which shares the Pro-Gly-Pro tail but derives from tuftsin; the pair is compared in Selank vs Semax. This guide brings together the library's material on Semax: history, chemistry, proposed mechanisms, model-system findings, handling and quality documentation.

Discovery and history

Semax traces back to research on short fragments of ACTH. Investigators took a fragment that lacked classic hormonal action and appended a small stabilizing extension, producing a peptide with a research profile very different from its parent hormone. It is a clear example of turning a short-lived fragment into a purpose-built research tool, and the history is also summarized in Semax discovery and history.

An ACTH fragment, re-engineered

The core sequence came from the ACTH(4-10) region. On its own this fragment does not drive the steroidogenic activity of full ACTH, which made it an appealing starting point for studying non-endocrine effects. The practical obstacle was stability: the native fragment is degraded too quickly in biological media to be a workable research subject.

The stability step

Adding a proline-containing tail, Pro-Gly-Pro, at the C-terminus solved most of that problem. Prolines impose conformational rigidity and, together with the terminal arrangement, shield the peptide from carboxypeptidase cleavage. The modified peptide could be characterized reproducibly, which opened the way to the neuroscience-oriented literature for which Semax became known. The structural details are covered in the next section and in the Semax chemistry article.

A regional research tradition

Semax was developed within a research program that also produced related short peptides such as Selank. The compounds share a design philosophy, short stabilized sequences derived from endogenous peptides, which is why they are often discussed together despite different parent molecules. Over time, Semax accumulated preclinical literature on neurotrophic and neuromodulatory readouts in model systems (references 1 and 2).

Separating chronology from evidence

Development history explains why particular neurobiological questions were asked; it does not resolve the mechanism. Early observations, later animal-model work and modern molecular assays are different layers of evidence and should not be blended into one claim. A careful reading asks which material was tested, in which model, with which endpoint, and whether an independent method confirmed the result.

Chemical structure and synthesis

Semax illustrates fragment stabilization clearly. Its identity is fixed by seven residues, and the placement of the stabilizing tail determines its behavior. The general importance of residue order is explained in understanding amino acid sequences.

The ACTH-derived core

The Met-Glu-His-Phe segment reproduces a short stretch of ACTH that lacks the hormone's corticosteroid-releasing activity. This decoupling of sequence from endocrine role is central to why the peptide is studied as a distinct research tool rather than as an ACTH mimic. The core contains an acidic residue (Glu), an imidazole-bearing histidine and an aromatic phenylalanine, so unlike Selank it absorbs at wavelengths above the peptide bond, though weakly.

The Pro-Gly-Pro tail

The tripeptide extension is the defining modification. It greatly extends the in-vitro half-life of the peptide while preserving the ACTH-derived core, and it is the structural basis of the mechanism discussed below. The tail does not make the peptide chemically indestructible: it improves resistance to some proteolytic routes but does nothing to prevent oxidation of the methionine.

Synthesis and purification

With only seven residues, Semax is well suited to standard Fmoc solid-phase peptide synthesis. The chain is assembled on a resin support, cleaved and deprotected, then purified by reversed-phase chromatography to remove truncated byproducts. The purified peptide is converted to a stable dry powder by freeze-drying (see what is lyophilization). Methionine-containing sequences need scavengers during cleavage to limit oxidation and alkylation, which is one reason a mass check for a +16 Da species is routine.

Stability must still be measured

Solution pH, temperature, light exposure, repeated handling and microbial contamination can all affect a short peptide preparation. Laboratory stability is therefore established by time-point analysis, not inferred from sequence. HPLC can reveal emerging degradation peaks, while mass spectrometry helps assign altered species. Because Semax and related short fragments differ by only a few residues, a complete sequence record and an unambiguous analytical match are essential for distinguishing the intended heptapeptide from truncated or closely related products.

Mechanism of action

Semax is studied in cultured neural cells and rodent systems, and its proposed mechanism is neuromodulatory and neurotrophic in character. The honest summary is that downstream expression and signaling changes are well described in models, while the initiating molecular target remains incompletely defined. See also the Semax mechanism of action article.

BDNF and TrkB

The central line of research concerns brain-derived neurotrophic factor (BDNF), a widely studied marker of neural plasticity. In rodent work, Semax has been reported to change expression of BDNF and its receptor TrkB in hippocampal and cortical tissue (reference 1). Studies frequently measure neurotrophic factor expression and downstream signaling in neural preparations; these readouts characterize how the peptide behaves under controlled conditions and do not identify its first molecular contact.

Gene-expression studies in ischemia models

Transcriptome analysis in an experimental rat brain-ischemia model reported altered expression of genes related to the immune and vascular systems after exposure to the peptide (reference 2). This broadened the picture beyond neurotrophins, but it remains a model-level observation that needs independent replication and protein-level confirmation.

Melanocortin-system context

Because the core comes from ACTH, interaction with melanocortin receptors has been proposed, and some work places Semax relative to other peptides sharing the parent hormone family. The fragment-based profile differs from full ACTH's endocrine activity, and a melanocortin interaction should be treated as a hypothesis until binding and receptor-perturbation data settle it.

No single confirmed receptor

An increase in a neurotrophin-related marker may indicate pathway modulation, but it does not tell us what the peptide bound first. Clarification requires binding studies, receptor perturbation, temporal ordering of early and late responses, and comparison with inactive or scrambled sequences. Metabolites of the short peptide may also contribute to measured effects in some preparations, adding a further variable. The most defensible account is a multi-pathway hypothesis supported by model-dependent readouts.

The role of the Pro-Gly-Pro extension is also a testable question: beyond prolonging stability, it may alter distribution or interactions in a model. Sequence variants, receptor perturbations and time-resolved signaling can separate these possibilities.

Preclinical research findings

Semax has been examined predominantly in neuroscience-oriented model systems. Preclinical characterization looks at how the sequence behaves in cell and animal preparations, always as controlled-model research. The library's summary is in Semax preclinical research.

Cell-culture preparations

Cultured neuronal and neural-progenitor systems are used to examine markers of neurotrophic signaling, including expression of neurotrophic factors and activation of associated pathways. They let investigators standardize variables and isolate the peptide's proposed readouts from the many confounders present in intact organisms.

Animal-model endpoints

Rodent studies have examined behavioral and biochemical endpoints associated with neural function. Typical readouts include neurotrophin expression, oxidative-stress markers and task-specific behavior, each interpreted strictly within its design. Model neural systems lack the complexity of intact nervous systems, and rodent findings do not translate directly across species.

Strengthening model-to-model comparison

Findings become more informative when the same molecular endpoint is measured across complementary systems. A cultured-cell result can establish timing and pathway sensitivity, a tissue preparation preserves local cell interactions, and an animal model can reveal feedback that isolated cells lack. Agreement across levels is useful; disagreement is equally important because it exposes context dependence. Reports should state peptide identity, assay timing, baseline conditions and blinding for behavioral endpoints. Comparison against the unstabilized ACTH fragment would help separate effects of the core sequence from those introduced by the Pro-Gly-Pro extension.

Stability as a practical enabler

The enzymatic stability conferred by the tail is what makes many of these experiments feasible; a rapidly degrading peptide would be difficult to characterize reproducibly. It also means that oxidation state should be reported, since an oxidized methionine species is a closely related impurity that can differ in behavior.

Handling, reconstitution and storage

The methionine residue is the main handling concern for Semax. Methionine oxidizes to its sulfoxide on prolonged exposure to air and light, creating a closely related impurity that can confuse analytical results. Minimizing headspace in the vial, limiting time at room temperature and avoiding repeated opening all reduce the effect. Compound-specific notes are in Semax reconstitution and storage, the general method is in the lyophilized-peptide reconstitution guide, and a fully worked example for another compound is how to reconstitute retatrutide step by step.

Preparing a stock solution

Let the vial reach room temperature before opening, use sterile technique, and add bacteriostatic water slowly down the inside wall of the vial rather than onto the cake. Dissolve by swirling; do not vortex or shake. Concentration is the mass in the vial divided by the diluent volume, and the reconstitution calculator performs the arithmetic for any vial size.

Worked example: 10 mg ÷ 2 mL = 5 mg/mL; to obtain a 1 mg/mL working solution from that stock, mix one part stock with four parts diluent. These are illustrative concentration calculations for bench planning.

Storage

The lyophilized powder is the most stable form and should be kept cold, dry and away from light until needed. The Pro-Gly-Pro tail improves resistance to peptidases in biological media but does not protect against oxidation in a storage vial, so cold, dark, aliquoted storage is the usual control. Label each aliquot with date and concentration, and avoid repeated freeze–thaw cycles; see storing research peptides for cold-chain principles. Matching procedures between Semax and Selank keeps cross-compound experiments comparable.

Purity, COA and quality

Because Semax differs from related short fragments by only a few residues, and because its methionine can oxidize, documentation matters more than usual. A lot-specific certificate of analysis should report chromatographic purity with the raw trace, a mass-spectrometry identity result consistent with about 814 Da, and ideally a note on oxidation state. Batch documents are on the CoA page; reading skills are covered in how to read a COA and understanding HPLC purity, and compound-specific checks are in Semax purity testing.

• The certificate refers to the same batch as the vial
• Chromatographic purity and mass identity are both reported, with raw traces
• The stated mass agrees with the expected value of about 814 Da
• The vial arrived sealed, and storage since receipt has been cold, dry and dark
• Any species at +16 Da is reported or can be requested

Noting the batch number alongside each dataset means lot-to-lot differences can be identified later instead of being mistaken for biological variability. Research-grade Semax is supplied as a lyophilized powder; where to buy Semax for research lists the documentation criteria worth checking when comparing suppliers.

Related compounds and comparisons

Semax's nearest relatives are Selank, with the same Pro-Gly-Pro tail but a tuftsin parent, and N-acetyl Semax amidate, a modified variant of the same scaffold.

See Selank vs Semax, the Selank research overview, and N-acetyl Semax amidate vs Semax for side-by-side detail. Product specifications are on the Semax product page.

Frequently asked questions

What is Semax derived from?

A fragment of adrenocorticotropic hormone, ACTH(4-10), extended with a stabilizing Pro-Gly-Pro C-terminal addition. The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, and the Met-Glu-His-Phe portion matches ACTH positions 4–7.

Does Semax retain ACTH's steroidogenic activity?

No. Steroidogenic activity depends on regions of the hormone that this short fragment does not contain, which is why Semax can be studied without adrenal stimulation as a confound.

Is there a single confirmed receptor for Semax?

Not a universally accepted one. Research more often examines downstream expression and signaling changes, such as BDNF and TrkB, than a single high-affinity target. Melanocortin-receptor interaction has been proposed but remains a hypothesis.

What is the molecular mass of Semax?

Approximately 813–814 Da, the reference value used for mass-spectrometric identity confirmation.

Why was Pro-Gly-Pro added to the ACTH fragment?

Short ACTH fragments are broken down quickly by peptidases. The proline-rich tail resists that cleavage, extending the time the peptide remains intact in biological media.

What is the main stability concern for Semax?

Oxidation of its methionine residue, which adds 16 Da and changes chromatographic behavior. Limiting exposure to air and light, and keeping the powder cold and dry, slows the process.

What model systems is Semax examined in?

Cultured neural cells and rodent models, including experimental ischemia. Readouts typically include neurotrophin mRNA and protein levels, cell-survival measures and behavioral paradigms.

How does Semax relate to Selank?

Both are stabilized regulatory peptides with a Pro-Gly-Pro tail, studied together to contrast scaffolds, but Semax derives from ACTH and Selank from tuftsin.

How is the stock concentration calculated?

Divide the mass in the vial by the diluent volume added, so 10 mg in 2 mL gives 5 mg/mL. The calculator on this site handles other vial sizes.

What documentation verifies a research-grade lot?

A lot-specific certificate of analysis showing HPLC purity with raw traces and a mass-identity result, ideally corroborated by third-party testing and reporting oxidation state.

Research-use statement

For laboratory research use only; not for human consumption. Everything in this guide describes laboratory observations in cells, tissues and animal models, together with analytical chemistry and bench handling. It is research education and not guidance for use in people or animals.

References

1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117:54–60.
2. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228.
3. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine. 2013;4:223–252.